Newly synthesized anticancer drug HUHS 1015 is effective on malignant pleural mesothelioma

The newly synthesized naftopidil analogue HUHS 1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO ‐211H, NCI ‐H28, NCI ‐H2052, and NCI ‐H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM. HUHS 10...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2014-07, Vol.105 (7), p.883-889
Main Authors: Kaku, Yoshiko, Nagaya, Hisao, Tsuchiya, Ayako, Kanno, Takeshi, Gotoh, Akinobu, Tanaka, Akito, Shimizu, Tadashi, Nakao, Syuhei, Tabata, Chiharu, Nakano, Takashi, Nishizaki, Tomoyuki
Format: Article
Language:English
Subjects:
Antineoplastic drugs
Antitumor agents
Apoptosis
Cancer
Cell cycle
Cell viability
Cisplatin
Laboratory animals
Mesothelioma
Mitochondria
Paclitaxel
Physiology
Prostate
Statistical analysis
Thermal cycling
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The newly synthesized naftopidil analogue HUHS 1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO ‐211H, NCI ‐H28, NCI ‐H2052, and NCI ‐H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM. HUHS 1015 induced both necrosis and apoptosis of MSTO ‐211H and NCI ‐H2052 cells. HUHS 1015 upregulated expression of mRNA s for Puma, Hrk, and Noxa in MSTO ‐211H and NCI ‐H2052 cells, suggesting HUHS 1015‐induced mitochondrial apoptosis. HUHS 1015 clearly suppressed tumor growth in mice inoculated with NCI ‐H2052 cells. Taken together, the results of the present study indicate that HUH S1015 could be developed as an effective anticancer drug for treatment of malignant pleural mesothelioma. HUHS 1015 was newly synthesized as an anticancer drug. HUHS 1015 induces apoptosis of malignant pleural mesothelioma cells with the potential greater than paclitaxel. HUHS 1015 could be developed as a promising anticancer drug for treatment of malignant pleural mesothelioma.
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.12429